NASDAQ$PBYI
Puma Biotechnology Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Puma Biotechnology reported a net loss for Q4 2020, impacted by COVID-19 challenges, but achieved NERLYNX revenues within guidance.
Puma Biotechnology reported a net loss of $15.0 million for the fourth quarter of 2020, with NERLYNX revenue at $50.0 million. The company continued to be impacted by COVID-19 challenges but met revenue guidance. Positive clinical milestones were achieved, and key milestones are anticipated over the next 12 months.
- Net NERLYNX revenue for Q4 2020 was $50.0 million, compared to $58.7 million in Q4 2019.
- Puma reported a net loss of $15.0 million, or $0.38 per share, for Q4 2020, compared to a net loss of $11.2 million, or $0.29 per share, for Q4 2019.
- Non-GAAP adjusted net loss was $5.5 million, or $0.14 per share, for Q4 2020, compared to non-GAAP adjusted net income of $0.3 million, or $0.01 per share, for Q4 2019.
- Net cash used in operating activities for Q4 2020 was $5.6 million, compared to net cash provided by operating activities of $1.6 million for Q4 2019.
Headline financials
Revenue & EPS history
Puma Biotechnology · Revenue · Quarterly
$52.6M
Revenue by segment
Puma Biotechnology · $52.4M total across 2 segments · Q2 2025
- Product revenue, net$49.2M—93.8%
- Royalty revenue$3.25M—6.2%
Forward guidance
Puma anticipates key milestones over the next 12 months, including completing enrollment and reporting top line data from the randomized cohort in the Phase II SUMMIT trial, conducting a pre-NDA meeting with the FDA, reporting Phase II data from the SUMMIT trial in non-small cell lung cancer patients, reporting data from the Phase II TBCRC-022 trial, conducting a meeting with the FDA to discuss the potential for an accelerated approval pathway, and receiving regulatory decisions for the extended adjuvant HER2-positive early stage breast cancer indication in additional countries.
Tailwinds
- Completing enrollment in the randomized cohort in the Phase II SUMMIT trial of neratinib in hormone receptor positive breast cancer that has a HER2 mutation in the second quarter of 2021
- Reporting top line data from the randomized cohort in the Phase II SUMMIT trial of neratinib in hormone receptor positive breast cancer that has a HER2 mutation in 2021
- Conducting a pre-NDA meeting with the FDA to discuss accelerated approval of neratinib in HER2-mutated hormone receptor positive breast cancer and HER2-mutated cervical cancer in 2021
- Reporting Phase II data from the SUMMIT trial of neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations in the second half of 2021
- Reporting data from the Phase II TBCRC-022 trial of the combination of Kadcyla plus neratinib in patients with HER2-positive breast cancer with brain metastases who have previously been treated with Kadcyla in the second half of 2021
Headwinds
- COVID-19 may continue to impact operations in 2021
- Potential risks and uncertainties could cause actual results to differ materially from anticipated results
- Reliance on forward-looking statements which speak only as of the date of the report
- Risk factors disclosed in periodic and current reports filed with the SEC
- Any adverse impact on Puma’s business or the global economy and financial markets from the global COVID-19 pandemic
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-1.6%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+4.4%
Avg return
30 days after
47%
21 / 45 earnings
Positive
+36.4%
Q4 2018
Best reaction
-45.8%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -2.8% | -6.0% | -5.8% | |
| Q4 2025 | -25.1% | -15.8% | -20.0% | |
| Q3 2025 | +21.8% | +1.8% | +8.2% | |
| Q1 2025 | -4.6% | -5.5% | +21.2% | |
| Q4 2024 | +19.7% | +18.4% | +5.0% | |
| Q3 2024 | -5.9% | +4.9% | +2.0% | |
| Q2 2024 | +6.7% | +12.3% | -30.4% | |
| Q1 2024 | -1.8% | -4.0% | -22.2% | |
| Q4 2023 | -10.8% | -21.5% | -19.7% | |
| Q3 2023 | +4.9% | +9.4% | +41.5% | |
| Q2 2023 | +5.8% | +13.3% | +2.5% | |
| Q1 2023 | +19.8% | +19.4% | +35.0% | |
| Q4 2022 | -20.1% | -26.6% | -23.1% | |
| Q3 2022 | +25.5% | +50.9% | +106.0% | |
| Q2 2022 | +23.5% | +17.4% | -17.0% | |
| Q1 2022 | -19.1% | -26.0% | -4.9% | |
| Q4 2021 | +13.5% | +25.7% | +34.2% | |
| Q3 2021 | -39.1% | -42.2% | -54.6% | |
| Q2 2021 | +3.6% | +3.6% | +7.9% | |
| Q1 2021 | +1.6% | -0.8% | +17.0% | |
| Q4 2020 | -11.9% | -11.9% | -12.6% | |
| Q3 2020 | -11.0% | +1.3% | +31.8% | |
| Q2 2020 | -5.7% | -7.9% | -11.6% | |
| Q1 2020 | +11.2% | +23.1% | +6.4% | |
| Q4 2019 | -2.4% | -18.8% | -43.9% | |
| Q3 2019 | +4.2% | +18.0% | +9.1% | |
| Q2 2019 | +26.7% | +25.8% | +22.1% | |
| Q1 2019 | -38.6% | -41.5% | -53.9% | |
| Q4 2018 | +36.4% | +35.3% | +35.9% | |
| Q3 2018 | -45.8% | -39.5% | -37.3% | |
| Q2 2018 | -7.5% | -7.1% | -2.1% | |
| Q1 2018 | -19.0% | -18.9% | -24.3% | |
| Q4 2017 | +8.7% | +16.7% | +4.1% | |
| Q3 2017 | -22.2% | -24.3% | -23.9% | |
| Q2 2017 | -11.6% | -1.7% | +28.0% | |
| Q1 2017 | +1.5% | +4.3% | +163.9% | |
| Q4 2016 | -10.6% | -8.3% | +1.4% | |
| Q3 2016 | +21.3% | -0.5% | -9.4% | |
| Q3 2015 | -9.6% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | -3.3% | — | — | |
| Q1 2013 | +3.7% | — | — | |
| Q3 2012 | -6.4% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +1.9% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro